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ABSTRACT 
 
Multiple Myeloma (MM) is a malignancy of plasma cells. The incidence 
worldwide has been reported to be 3-4/100 000 of the population. The exact 
aetiology is not known, but several factors have been implicated in the aetio-
pathogenesis of the disease. 
Chromosomal abnormalities are well documented in MM. Their detection is 
important, as some of the cytogenetic abnormalities such as the 13q deletion 
are associated with a poor prognosis. Knowledge of the prognostic factors 
guides the clinician with respect to the appropriate management of the 
patient.  
Prior to the use of fluorescence in situ hybridisation (FISH) as a technique for 
detecting cytogenetic abnormalities in MM, progress was slow in this field 
because of the difficulty of obtaining analysable metaphases in view of the low 
proliferative activity of plasma cells. FISH has significantly improved the 
detection rate over conventional cytogenetics. 
Objective: The present study set out to determine the proportion of patients 
with MM who have a detectable chromosome 13q deletion using   
conventional cytogenetic and FISH analysis. The FISH technique was 
specifically studied to see if the detection rate of the 13q deletion is improved 
compared to conventional cytogenetics. Furthermore, the cytogenetic 
abnormalities detected were correlated with the course of the disease, as well 
as other parameters of prognostic significance. 
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Methods: Bone marrow aspiration specimens were obtained from thirty (30)  
patients with MM. Both newly and previously diagnosed patients were  
included.  
The sample size was however reduced to twenty (20) because of the  
need to optimise the technique and improve signal detection. 
Conventional cytogenetic and FISH analysis was performed using the LSI 
D13S319 DNA probe as the test probe, and the centromeric alpha 11 and 18 
as control probes. The analysis was carried out by two observers.  
Results: In the current study, the detection of chromosomal aberrations was 
much better with FISH analysis compared to conventional cytogenetics i.e. 
25% versus 5%. 
Of all the patients with chromosomal aberrations, 25% (5/20) had the specific 
deletion 13q14 (D13S319). Most of our patients (70%) presented with stage  
III disease. 60% of those were positive for deletion  13q14 (D13S319), i.e 3/5 
patients had stage III disease. However, there was no correlation between 
disease stage and chromosome status, as the majority of the patients 
presented with advanced stage disease, irrespective of their chromosomal 
status. Other factors of prognostic significance such as the haemoglobin level, 
beta-2 microglobulin and creatinine levels were not found to correlate with the 
presence of the chromosomal aberration but with disease stage. Furthermore, 
median survival did not correlate with the presence of the chromosomal 
abnormality.  
Conclusion: FISH analysis improves the detection rate of chromosomal 
abnormalities in MM compared to conventional cytogenetics. The prevalence 
of 13q14 deletion in our patient population is lower than that reported in the 
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literature (25% vs 30-80%). No correlation was found between the presence 
of the deletion 13q14 (D13S319) and mortality, stage of disease and 
laboratory parameters that have been associated with poor prognosis in MM 
i.e. haemoglobin, Beta-2-microglobulin and creatinine levels. The prognostic 
significance of deletion 13q14 (D13S319) in MM could not be established 
from this study. A prospective study with a larger sample and using probes 
covering the whole extent of chromosome 13q may possibly yield different or 
more conclusive results. The use of other techniques such as gene 
expression profile analysis would probably be of value in determining the 
prognostic significance of 13q14 lesions in MM. 
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CHAPTER 1 
 
1.0 LITERATURE REVIEW 
 
1.1 Introduction 
 
Multiple myeloma (MM) is a malignant proliferation of plasma cells, which are 
terminally differentiated B lymphocytes. MM accounts for approximately 10 to 
20% of all haematopoietic malignancies (Cigudosa et al, 1998). On average, 
the incidence worldwide is reported as 3-4/100 000 of the population (Morgan, 
1999; Muir et al, 1987; Alexanian, 1985; Pottern and Blattner, 1985). MM is 
characteristically a disease of middle and old age. The incidence increases 
with increasing age and reaches a peak during the seventh decade of life. 
The median age at diagnosis is 65 years. Myeloma case series from Africa 
have suggested a younger median age at diagnosis (approximately 5 - 10 
years younger) than in the Western world, probably reflecting the younger age 
structure of the African population (Patel et al, 1992; Mukiibi and Kyobe, 
1988). There is a slight male predominance, and the disease occurs twice as 
often in blacks as it does in caucasians (Muir et al, 1987; Alexanian, 1985; 
Pottern and Blattner, 1985; Blattner et al, 1979). 
The clinical presentation of MM is exemplified by bone pain (especially 
backache), anaemia, recurrent infections, renal dysfunction, and 
hypercalcaemia.  Other features include pathological fractures, osteopenia, 
vertebral compression fractures, spinal cord compression, hyperuricaemia, 
plasmacytomas, abnormal bleeding tendency, hyperviscosity and amyloidosis 
(Malpas, 1995; Patel, 1994; Kyle, 1990). 
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The diagnosis of MM is based on the WHO diagnostic Criteria/ International 
Myeloma Working Group Criteria (see appendix 3 for details)  
All three of the following criteria are required to establish a diagnosis. 
i) M-protein in serum or urine (see figure 1.1) 
ii) Bone marrow clonal plasma cells or plasmacytoma 
iii) Related organ/tissue impairment  (CRAB:hypercalcemia, renal 
insufficiency, anaemia, bone lesions) 
The National Cancer Institute Criteria are detailed in appendix 2. 
 
                   α1  α2  β                               α1   α2    β                                                        
 
Figure1.1 Electrophoresis pattern in Multiple Myeloma 
 
 
 
 
Figure 1.2 Plasma cell morphology 
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Once the diagnosis of MM is established, the disease is staged according to 
the Durie and Salmon staging system (Durie and Salmon, 1975 - see 
Appendix 1). 
In addition to the above staging system, a number of other prognostic factors 
have been developed. These prognostic factors are related to the tumour 
burden or intrinsic malignancy. Examples of prognostic factors related to the 
tumour burden include Beta-2 microglobulin, ‘M’ component, percentage of 
bone marrow plasma cells, osteolytic lesions, haemoglobin and serum 
calcium. Those that are related to the intrinsic malignancy include: plasma cell 
labelling index, CRP, IL-6, albumin, genetic alterations/cytogenetic 
abnormalities, plasma cell phenotype, thymidine kinase, lactic 
dehydrogenase, immune dysregulation and neopterin (Boccadoro and Pileri, 
1995). 
 The vast majority of patients (approximately 90%) require therapeutic 
intervention once the diagnosis is established. In such patients therapy can 
prolong and improve quality of life. The remaining 10% demonstrate an 
indolent course, with slow progression of disease over many years.  
Treatment may be broadly classified as supportive and/or specific. Supportive 
care is an essential component of the disease. Supportive care is generally 
directed at the anticipated complications of the disease. Analgesics, 
allopurinol, increased fluid intake, antibiotics, erythropoietin, haematinics, 
transfusion of blood and blood products, dialysis and plasmapheresis are 
examples of supportive care used in the treatment of MM.  Hypercalcaemia 
responds well to hydration, natriuresis, mobilisation, glucocorticoids and 
importantly to bisphosphonates. Bisphosphonates have pleotropic effects 
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including inhibition of osteoclastic bone resorption, reduction in bone pain and 
possible anti-tumour activity (Aparicio et al, 1998; Berenson et al, 1998). 
Most of the specific modalities of therapy used are not curative, except 
possibly for allogeneic stem cell transplantation. This, together with innovative 
therapies for MM (see p.5) represent a new treatment paradigm, targeting 
tumour cells and their microenvironments to achieve greater tumour 
cytoreduction and potentially a cure (Munshi, 2004). 
The standard induction therapy for MM using a combination of oral Melphalan 
and Prednisone (MP) achieves complete responses in only 5% of patients 
and improves median survival to 36 months (Barlogie et al, 2004). In 1998, 
the Myeloma Trialist’s Collaborative  Group performed a meta-analysis of data 
from 6633 patients from 27 randomised trials. They found higher response 
rates with combination chemotherapy (CCT) than with MP (60% v 53.2%, 
respectively; P <0.00001), but no significant differences in response duration 
or overall survival (OS). With high dose melphalan-based autotransplants, 
especially in a tandem transplant setting, complete response rates exceeding 
50% have been reported. At ten years, in the absence of cytogenetic 
abnormalities (especially abnormalities of chromosome 13, i.e. 13q deletion 
and hypodiploidy), 25% of patients remain event-free and 40% are alive 
(Shaughnessy et al, 2003). Although this represents a significant 
improvement, the development of chemotherapy-resistant disease remains an 
important therapeutic challenge.  
Current research is focusing on attempts at overcoming resistance. New and 
re-emerging approaches specifically target the mechanisms critical for MM 
cell growth and survival in the bone marrow microenvironment.    Some of 
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these novel therapeutic agents include thalidomide (Weber et al, 2003; 
Yakoub-Agha et al, 2002) and its analogue immunomodulatory drugs (ImiDS) 
e.g. Revlimid (Lenalidomide) (Richardson et al, 2002), the proteosome 
inhibitor Bortezomib (Richardson et al, 2003) and arsenic trioxide (Munshi et 
al, 2002), all of which have demonstrated clinical anti-MM activity even in 
patients with refractory and relapsed disease. Ongoing studies will define the 
exact role of these agents (i.e. as single agents/combination with other agents 
such as dexamethasone and where in the course of disease they should be 
introduced – at diagnosis; post-autotransplants etc.) 
 
1.2 Pathophysiology 
Immunoglobulin heavy chain (IgH) analysis reveals that the malignant plasma 
cells arise from post-germinal centre B lymphocytes that have undergone 
antigen selection, isotype switch recombination and somatic hypermutation of 
their Ig (immunoglobulin) genes. The plasma cells then migrate to the bone 
marrow where they proliferate (van Riet et al, 1998). Interactions with marrow 
stromal cells facilitate homing and growth of myeloma cells. Stromal cells 
produce interleukin 6 (IL-6) – an important growth and differentiating factor for 
plasma cells.  
The mechanism by which these cells undergo malignant transformation is not  
clear. Hallek et al (1998), proposed a multi-step transformation process 
starting with a normal plasma cell that progresses to Monoclonal 
Gammopathy of Unknown Significance (MGUS), where the cells are 
immortalised, but not transformed, and then to intra-medullary myeloma 
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where the cells have become malignant, and finally to extra-medullary 
myeloma. 
The malignant process may be initiated by an Ig gene translocation related to 
the Ig recombination process, that results in ectopic expression (dysregulated 
expression) of an oncogene such as cyclin D1, c-myc etc., caused by the 
juxtaposition to strong regulatory sequences of the IgH locus and resulting in 
immortalization of the malignant clone. 
Dysregulated c-myc levels may be the first growth stimulatory signal in the 
development of myeloma. C-myc, together with p53, counteracts pRB and 
p107 mediated growth arrest signals and thus stimulates cell proliferation. 
Additionally, the myeloma cells may be susceptible to cytokine-deprived or 
growth factor-deprived apoptosis. There is early acquisition of chromosomal 
instability, with frequent multiple trisomies present even in MGUS and  
monosomy 13 in myeloma. 
The second proliferative signal may be activation of the ras/MAPK (mitogen-
activated protein kinase) pathway, by secretion of IL-6 and related cytokines 
from the bone marrow stromal cells in response to adhesion of myeloma cells. 
Activation of the ras/MAP kinase pathway prevents c-myc induced apoptosis, 
and results in up-regulation of bcl-2 and other anti-apoptotic factors that 
prolong survival of myeloma cells.  The ensuing constitutive ras activation 
results in higher expression of bcl-2 and endogenous IL-6 secretion by 
myeloma cells. The hypermutational process onto ras or a tumour suppressor 
gene on chromosome 13, results in selection of a single clone for malignant 
expansion. Activating ras mutations have been noted in 35-50% of MM 
patients. Most of these involve both N- and K–ras.  
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Tumours with t(4;14)(p16.3;q32) can have activating mutations of ras  or 
fibroblast growth factor receptor 3 (FGFR3). Mutations of K but not N-ras have 
been associated with shorter survival (Liu et al, 1996; Bezieau et al, 2001)   
In the advanced stages of the disease, loss of p53 function occurs, leading to 
genomic instability as evidenced by complex karyotypic abnormalities and 
translocations.  
Deletion 17p13 is detected in 5% of the patients at diagnosis and 20-40% in 
advanced MM or plasma cell leukaemia (Mazars et al, 1992) 
The secondary IgH translocation to a variety of loci occurs by mechanisms 
unrelated to physiologic Ig recombination processes, that may reflect the 
presence of a more general genomic instability. Further mutations, like p53, 
lead to stroma-independent growth, and escape of myeloma cells from the 
bone marrow micro-environment (Bergsagel et al, 1999; Hallek et al, 1998; 
Feinman et al, 1997). 
 
1.3 Aetiopathogenesis 
The exact aetiology of MM is unknown. A number of factors have been 
suggested as causative. Exposure to ionizing radiation and agriculture are the 
most common (Patel, 2000; Demers et al, 1993; Shimizu, 1990; Cuzick and 
De Stavola, 1988; Steineck and Wiklund, 1986; Pottern and Blattner, 1985; 
Cuzick, 1981). One of the more convincing risk factors for myeloma has been 
exposure to ionizing radiation. This has been documented in the studies of 
survivors of the atomic bomb explosions in Hiroshima and Nagasaki, Japan, 
in 1945 (Ichimaru et al, 1982). Radiation exposures include exposure to 
ionizing radiation (atomic bomb; high dose) and occupation related radiation 
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such as nuclear workers and radiologists, and recipients of therapeutic and 
diagnostic radiation. In contrast to individuals who were exposed to high dose 
irradiation, the excess risk of myeloma in association with low dose radiation 
exposure remains controversial.  The target of ionising radiation is believed to 
be the proto-oncogenes in DNA. 
In the reports in which an association with farming has been suggested (see 
references above), because of the wide variety of different exposures, it is not 
possible to determine whether oncogenic zoonotic viruses, pesticides 
(including herbicides and insecticides), agricultural chemicals or some 
combination of exposures is responsible for the increased risk of myeloma. 
Other  associations or specific exposures that may increase myeloma risk 
among farmers include dairy and sheep farming, exposure to cattle, poultry 
and other farm animals, orchard farming, exposure to grain dust, aflatoxins, 
paints and solvents, wood treatment, chemicals used for fencing, engine 
exhaust from farm equipment, welding fumes and pollen (Pearce and Reif, 
1990; Blair et al, 1985).  
Exposure to benzene has also been implicated as an aetiological factor. 
Recent data, however, appear to dispute this association (Bergsagel, et al, 
1999). 
 Bergsagel et al (1999), in their review of benzene and myeloma concluded 
that in contrast to the strong evidence linking high levels of benzene exposure 
to an increased risk of developing acute myelogenous leukaemia, there is no 
scientific evidence to support a causal association between exposure to 
benzene or other petroleum products and the risk of developing MM. 
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Chronic antigenic stimulation (CAS) has been suggested to be a risk factor in 
the development of myeloma. In addition, there is growing evidence that CAS 
could facilitate the progression of the disease. This may occur via (IL-6) 
interleukin-6. Overproduction of IL-6 occurs in a number of other diseases 
such as rheumatoid arthritis, systemic lupus erythematosus, trauma, acute 
infectious neural disease, cardiac myxoma and transplantation (Wolverkamp 
and Marquet, 1990).  It is plausible that these conditions could be regarded as 
potential risk factors for the development of myeloma via IL-6 over production. 
Another pathway by which CAS could be associated with myeloma is through 
production of a monoclonal protein (M-protein), which may be transient or 
chronic. Transient production occurs normally in response to trauma, drugs 
and infections with specific antigens (Haas et al, 1990). Chronic production 
can occur in response to rheumatoid arthritis, infections, malignancy, 
neurological and dermatological diseases, chronic liver disease etc. (Passweg 
et al, 1996; Blade and Kyle, 1995).  
Cytokines play an important role in the pathogenesis of MM.  Interactions with 
marrow stromal cells facilitate homing and growth of myeloma cells. The most 
commonly implicated cytokines are interleukin-1 beta (IL-1β), tumour necrosis 
factor alpha (TNFα), IL-3, IL-6, IL-5, IL-10, IL-21, insulin-like growth factor I 
(IGF-I), vascular endothelial growth factor (VEGF) and transforming growth 
factor beta I (TGF-βI) (Chauhan et al, 1996; Urashima et al, 1996; Urashima 
et al, 1995) .  
IL-6 may act both as an autocrine and paracrine differentiating factor for 
plasma cells.IL-6 is a potent stimulator of B-cell differentiation and is essential 
for the survival and growth of myeloma cells (Klein et al, 1989; Kawano et al, 
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1988). Additionally, myeloma cells can stimulate stromal and bone cells to 
produce large amounts of IL-6 (Carter et al, 1990). IL-6 in turn stimulates the 
myeloma cells as well as cells in the bone marrow microenvironment to 
produce osteoclast activating cytokines including tumour necrosis factor α and 
IL-1β. These cytokines upregulate stromal cell secretion of receptor activator 
of nuclear factor к B ligand (RANK-L), which stimulates osteoclast production. 
Excess osteoclastic activity may manifest as lytic bone disease and 
hypercalcaemia. Secretion of osteoprotegerin, the major inhibitor of RANK-L 
is reduced (Croucher and Apperley, 1998). In addition Dickkopf-1 which is 
thought to be produced by myeloma cells or stromal cells in association with 
myeloma cells  inhibits  Wnt-signaling, which is important for osteoblast 
differentiation.  This results in inhibition of osteoblast activity in MM (Erming et 
al, 2003). Other osteoblast inhibitors are also thought to play a role e.g 
(IGFBP-4) insulin like growth factor binding protein-4, secreted frizzled 
receptor-like proteins(sFRP-2/3) and IL-7 (Erming et al, 2003) 
Recently, human herpesvirus-8/Kaposi sarcoma herpesvirus  
(HHV-8/KSHV) has been implicated in the aetiopathogenesis of MM (Rettig et 
al, 1997). Involvement of the virus in the development of myeloma was 
suggested after detection of KSHV DNA sequences by polymerase chain 
reaction (PCR) in the dendritic cells of 15/15 patients with MM and 2/8 
patients with MGUS, but not from malignant cells or bone marrow dendritic 
cells from normal individuals or patients with other malignancies (Rettig et al, 
1997). The association was biologically plausible as KSHV was found to 
encode an IL-6 homologue that was capable of stimulating growth and 
preventing apoptosis of murine and human myeloma cell lines (Burger et al, 
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1998; Moore et al, 1996). However, following on the initial positive reports, a 
number of authors have not been able to confirm this association and the role 
of KSHV in MM remains controversial (Olsen et al, 1998; Tarte et al, 1998). 
In a local study by Patel et al (2001), the positivity of KSHV DNA sequences 
in MM adherent cell cultures was found to be 23.5%. This is similar to the 
background sero-prevalence rate for KSHV in South Africa. Based on these 
findings, there does not appear to be a clear association between MM and 
KSHV in the local population.   
 
 
1.4 Genetics of Multiple Myeloma 
 
The familial occurrence of MM is well recognized. The first documented report 
was by Mandema and Wildervanck, in 1954. Since then, a number of authors 
have reported its occurrence, mainly in siblings and first-degree relatives of 
multiple myeloma patients (Herrinton et al, 1995). 
The role of genetic factors in the pathogenesis of the disease is still uncertain, 
but MM per se is not regarded as an inherited disorder.  
Genetic factors may be used to explain the differences in incidence between 
the different ethnic groups. Evidence for the role of genetic factors in the 
pathogenesis of the disease is based on striking differences in the incidence 
of monoclonal gammopathy and plasmacytomas in different inbred strains of 
mice (Potter et al, 1975; Radl and Hollander, 1974); racial differences in the 
incidence of MGUS (monoclonal gammopathy of undetermined significance) 
and MM in humans (Riedl and Pottern, 1992); the association of an increased 
risk of developing myeloma with certain human leucocyte antigens (HLA) 
(Pottern et al, 1992); and the occurrence of familial MM. 
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A number of publications have suggested an association of HLA phenotypes 
with MM. These involve class I (A, B and C), as well as class II (DR) antigens. 
There is no consistent or specific MM HLA phenotype. 
Miller (1974) found that in an analysis of HLA antigens in adults with various 
forms of haematological malignancies, there was an increase in HLA-5 and 
HLA-13 in patients with lymphoproliferative disorders, including multiple 
myeloma, compared to normal controls. Earlier studies of MM patients 
reported an association with the B locus, in particular HLA-B5;  with a 
significantly elevated risk of developing myeloma (Festen et al, 1976; Mason 
and Cullen, 1975; Miller, 1974). A significantly higher frequency of HLA-B18 
antigen has also been documented in myeloma (Smith et al, 1974; Bertrams 
et al, 1972). An association with the C locus involving HLA-Cw5 and HLA-
Cw6 antigens has also been reported (Leech et al, 1983, Pottern, et al, 1992). 
There is a paucity of data available regarding the involvement of the D locus 
and MM. Muylle et al (1982), in their study of 28 patients, found no 
association with HLA DR antigens. 
Patel et al (2002), in their study of 62 South African black patients with MM, 
showed a statistically significant association with HLA-B18 and not with any 
other published (MM associated) HLA phenotype.  
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1.5 Chromosomal abnormalities in Multiple Myeloma 
 
Chromosomal (cytogenetic) abnormalities are well described in MM. Both 
numerical and structural abnormalities have been reported (Maslovsky et al, 
1999; Bataille and Harosseau, 1997; Dewald et al, 1985). 
Detection of these abnormalities has been difficult in the past using 
conventional cytogenetics, due to the lack of adequate analysable 
metaphases, because of the low proliferation rate of plasma cells. The 
technical difficulties with culturing  and  banding  contributes to this problem 
(Zhao et al, 2000). Other factors which compound the problem include the 
variable pattern of bone marrow infiltration, the complexity of the numerical 
and structural abnormalities described, and the absence of a common or 
specific abnormality (Avet-Loiseau et al, 1999). Conventional cytogenetics 
reveals abnormal karyotypes in only 40% of the patients at diagnosis and 
63% of patients with advanced disease (Zojer et al, 2000; Fonseca et al, 
1999; Maslovsky et al, 1999; Cigudosa et al, 1998). 
 Most of the abnormalities are reported in patients with advanced disease 
(stage III), which might suggest an association of genetic abnormalities with 
disease progression.  
The chromosomal abnormalities that were detected and found to be recurrent 
in MM include: abnormalities of chromosomes 1, 3, 5, 7, 9, 11, 15, 19, 21, 
deletions of 13q and reciprocal translocations involving 14q32 (Avet-Loiseau 
et al, 1999; Garcia-Sanz et al, 1999). 
Less commonly, abnormalities of other chromosomes such as chromosome 8, 
12, 16, 17 and 18 have been associated with myeloma (Fonseca et al, 1999; 
Tricot et al, 1995; Dewald et al, 1985; Lewis and Mackenzie, 1984). 
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Deletions of 13q14 and rearrangements of 14q32 (mainly translocations)  
have been described as the most frequently encountered chromosomal 
abnormalities in association with multiple myeloma (Zojer et al, 2000;  
Morgan, 1999; Cigudosa et al, 1998; Bergsagel et al, 1996).  
Some chromosomal abnormalities have been associated with a poor 
prognosis. These  includes any translocation, e.g.  t(4;14), t(14;16), 
abnormalities involving 11q, deletions of 13q14 (Fonseca et al, 1999; 
Cigudosa et al, 1998) and deletions of chromosome 17 (Fonseca et al, 1999). 
Chromosomal abnormalities associated with a good prognosis and long-term 
survival are trisomies of chromosomes 6, 9 and 7 (Perez-Simon et al,1998). 
The rate of detection of cytogenetic abnormalities is higher with flow 
cytometric and FISH (Fluorescence in situ hydridisation) analysis.  
Abnormalities have been detected in the vast majority (80-90%) of patients 
with myeloma using FISH, irrespective of the stage of the disease (Tabernero 
et al, 1996; Drach et al, 1995; Barlogie et al, 1989).  
Flow cytometric analysis of DNA content of myeloma cells in G0/1 phase has 
revealed aneuploidy in 30-80% of the patients (Fonseca et al, 1999; Garcia-
Sanz et al, 1999; Barlogie et al, 1989). Based on the flow cytometry 
aneuploidy data and the FISH analysis,  conventional cytogenetics fails to 
detect the majority of patients with chromosomal abnormalities.  
Patients in relapse and progressive disease show a higher frequency (30- 
60%) of chromosomal abnormalities compared to newly diagnosed patients 
(Lai et al, 1995; Sawyer et al, 1994; Gould et al, 1988; Dewald et al, 1985). 
This is in line with the multi-step theory of MM oncogenesis (Hallek et al, 
1998). 
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1.5.1  Chromosome 13 in Multiple Myeloma 
Deletion (partial or complete) of chromosome 13q has been shown to be the 
most frequently encountered chromosomal loss in MM (see figure 1.3). It is 
detected in 46% of the newly diagnosed and 73% of relapsed patients with 
MM (Zojer et al, 2000). Shaughnessy et al (2000), reported 13q deletions in 
86% of MM patients compared to normal donors. Chang et al (1999), reported 
13q deletions in 30% of patients with normal karyotypes on conventional 
cytogenetics.  In a study by Avet-Loiseau et al (2002), monosomy 13 was 
found to be the most common chromosome 13 abnormality, detected in 92% 
of their patients. In a study comparing patients with MGUS that progressed to 
MM and patients with de novo MM, deletion 13q has been reported in 70% of 
patients with MGUS/MM compared to 40% of patients with de novo MM. 
The prevalence of 13q deletion is reported to be 30-55% with interphase FISH 
(Fonseca et al, 2002; Shaughenessy et al, 2000).  
Chromosome 13q deletion appears to be a good candidate event in the 
malignant transformation of myeloma plasma cells (Avet-Loiseau  et al, 1999). 
The minimal common region of deletion on 13 is thought to be in band 
13q14.3, which spans the region containing the RB-1 gene, loci D13S319 and 
D13S272  (see figure 1.6) (Viguie, 2001; Konigs et al, 2000). 
The majority of these deletions are sub-microscopic and only detected during 
interphase. 
The possibility of a putative tumour suppressor gene cannot be excluded, 
although the minimal deleted region is difficult to demonstrate.  A candidate 
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tumour suppressor gene has been localised to 13q14.3 because this region is 
also deleted in Chronic Lymphocytic Leukemia and Non-Hodgkins lymphoma. 
 
Figure 1.3 Schematic representation - Chromosome 13q deletion 
 
This gene has however not been characterised and its role in the 
pathogenesis of multiple myeloma is not known. Chromosome 13q deletion 
has apparently  been associated with IgA subtype myeloma, elevated beta-2 
microglobulin level, higher proliferation rate and advanced age (Tricot et al, 
1995). 
It is recognised that the 13q14 chromosomal abnormality has also been 
associated with inferior clinical outcome despite treatment (Zojer et al, 2000; 
Fonseca et al, 1999;Tricot et al, 1995). The prognostic importance of deletion 
13q14 is thought not to be in isolation, but in association with a high serum 
beta-2 microglobulin level, percentage bone marrow plasma cells (Viguie, 
2001) and non-hyperdiploidy (Shaughnessy et al, 2003).  Avet-Loiseau et al 
(2002), have however found elevated serum beta-2 microglobulin levels to be 
more closely associated with 14q32 abnormalities than with 13q14 deletion. 
Deletion 13q14 in MM is rarely observed as a sole abnormality both in 
hyperdiploidy and hypodiploidy karyotypes, but has a higher incidence in 
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hypodiploid forms, such that the prognostic value of deletion 13q14 is thought 
to be related to the ploidy (Viguie, 2001). Some authors however believe that 
the two independently confer a  poor prognosis (Anthanasios et al,  2002) 
 The most common chromosomal abnormalities associated with deletion 
13q14 are translocations of chromosome 14q32. These abnormalities do not 
seem to occur randomly, but are rather interconnected in MM. 
Based on the various combinations found, MM could be stratified into 
four groups, viz. patients without 14q32 abnormalities but with deletion 13q14; 
patients with translocation 14q32 and deletion 13q14;  t(4,14) and t(14;16), 
patients with other abnormalities of 14q and deletion 13q14; and patients with 
14q32 abnormalities, but no deletion 13q14. 
 
Figure 1.4  Chromosome 13 ideogram showing the mapping of the 
probes/genes. 
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In a study by Shaughnessy et al, using an 11-probe panel spanning the long 
arm of chromosome 13, deletions were detected in 86% of patients in different 
combinations. 
 
 
Figure 1.5  Vysis  probe to demonstrate the location of D13S319 with regards 
to the RB-1 gene. 
Heterogeneity was documented for the location, frequency and extent of the 
regions deleted in all patients. Of the deletions detected 75% were accounted 
for by the D13S272 locus, and 66% by the D13S31 locus, suggesting their 
importance in the disease process. Both loci were concurrently deleted in 
59% of the patients.  D13S319 is located between RB-1 and D13S25.   
The RB-1 and D13S319 were deleted in 52% and 70% respectively of newly 
diagnosed patients. 
These two loci (RB-1 and D13S25) appear to be deletion “hot spots” 
according to some authors (Shaughenessy et al, 2000). 
In an earlier study by Zojer et al (2000), the prognostic importance of deletion 
13q14 was reported, based on deletions of the RB-1 gene and D13S319 
locus, where each was accounted for by 52% and 70% respectively. 
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This makes it difficult to determine whether the adverse prognostic 
implications were as a result of the deletions in isolation, or in combination 
with other loci being deleted. 
Deletion of chromosome 13q14 implies both rapid disease recurrence and 
initial drug resistance (Shaughnessy et al, 2000). In trying to determine the 
biological implications of deletion 13q14 some groups  have shown that 
deletion 13q14 is frequently   associated with lambda type light chain, higher 
proliferation rate, lower serum monoclonal peak concentration, and increased 
angiogenesis in some but not all patients (Fonseca et al, 2002, Moreau et al, 
2002) 
 
 
 
 
 
 
 
 
 
 
Figure 1.6  The minimally deleted region of 13q14 in CLL  
(Adapted from Chang et al, 1999) 
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1.5.2  Chromosome 14q32 in Multiple Myeloma 
Avet-Loiseau et al (1999), reported rearrangements involving the IgH gene at 
14q32 in 60-75% of their patients. Nishida et al (1997),  reported similar 
rearrangements in 73% of their patients. Bergsagel and colleagues (1996), 
have shown that translocations involving the breakpoint at 14q32 to be nearly 
universal in MM. The rearrangements of 14q32 were found in all tumour cells, 
which strongly implicated these rearrangements as early events preceding 
clonal expansion. This translocation involves numerous partners. Those 
described include chromosomes 11, 4, 8, 16 and 18 (Dewald and Jenkins, 
1991; Gould et al, 1988; Dewald et al, 1985). Chromosome 11q13 and 4p16 
have been found to be the main partners (Avet-Loiseau, et al 1999; 
Bergsagel, et al, 1996). These translocations have not been found to form 
fusion genes, but to cause juxtaposition of oncogenes with promoter regions 
(Fonseca et al, 1999).  
Abnormalities of 14q32 have also been associated with a poor prognosis. 
It has been shown that t (11;14 ) in particular is associated with  a grave 
prognosis (Fonseca et al, 2002). 
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1.6 Aims and objectives of the study 
 
The aims and objectives of the study are: 
1. To determine if the detection rate of chromosomal abnormalities 
    improves with FISH analysis compared to conventional cytogenetic studies. 
2. To determine the proportion/percentage of patients with chromosome       
     13q14 deletion in the study population, and 
3. To correlate the cytogenetic findings with known clinical and    
laboratory features of prognostic significance in our study population. 
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CHAPTER 2 
 
2.0 PATIENTS AND METHODS 
 
2.1 Patients 
 
The study population consisted of adults with a confirmed diagnosis of MM. 
The patients were diagnosed , being treated and followed up by the Clinical 
Haematology Division, Department of Medicine, Chris-Hani Baragwanath 
Hospital (CHBH). The study period was from January 1999 to July 2003.  
Ethical clearance was obtained from the Committee for Research with Human 
Subjects (Medical) of the University of the Witwatersrand - Reference Number 
14/49. 
During this period, all consecutive patients were considered for the study, but 
only patients with bone marrow aspirate specimens that had adequate tumour 
representation were selected for the study.  
2.2  Materials and Methods 
The study had both a prospective (13 patients) and a retrospective  
(7 patients) arm. Bone marrow aspirate smears were retrieved from storage 
for the retrospective arm. Two extra bone marrow aspirate smears were 
prepared and 1-2mls was sent for conventional cytogenetic studies for all the 
new patients.  The sample cultures were collected in RPMI ( Roswell Park  
Memorial Institute ) medium with fetal calf serum and antibiotics. Growth was 
not stimulated as per standard operating procedure. 
The pre-hybridisation technique had to be optimised for the older specimens, 
for FISH preparation. 
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Some of the strategies employed were, overnight fixation, rehydration, 
shortening of the diamino-2-phenylindole (DAPI) counterstaining time, 
extended washing times and repeat hybridisation. 
FISH analysis was performed using the LSI* D13S319 spectrum orange, DNA 
probe specific for the D13S319 locus, purchased from S.A. Scientific Group 
(Vysis), as the test probe, and a centromeric chromosome 11-alpha and 18-
alpha probes as controls. The method as per standard operating procedure 
involved fixation, dehydration in ethanol series of varying concentration, 
denaturation, followed by overnight hybridisation in a humidified chamber at 
37° Celcius. This was followed by a washing step and Deamino-2-
phenylindole (DAPI) counter-staining. 
Analysis was carried out using the BX 61 Olympus Flourescence Microscope   
with computer software for capturing the pictures. 
 Hybridisation signals were enumerated in 50 to 100 cells. Results were 
analysed independently by two individuals. The cut off for the number of 
positive cells was set at five (i.e if signals were detected in less than five cells 
then the test was regarded as having been unsuccessful, only cases with 
signals  in five or more cells were reported).  
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CHAPTER 3 
3.0 RESULTS 
 
The initial sample size was thirty patients. The number was reduced due to  
 
problems encountered with old bone marrow specimens, where hybridisation  
 
failed and signal detection was not possible even after optimisation of the  
 
technique.  Finally, results of twenty of the total number of patients attempted  
 
were evaluated.  The characteristics and results of the patients in whom  
 
conventional cytogenetics was attempted and FISH was successful are  
 
depicted in tables1.1 and 1.2.  
 
 There were 15 males and 5 females with a male to female ratio of 3:1. The  
 
age ranged from 35 to 77 years with an average of 58 years. 
 
Based on the Durie and Salmon staging, four patients presented with stage I,  
 
 one with stage II and fifteen with stage III disease.  
 
The dominant isotype was IgG (70% )  followed by IgA (25%) and 5% light  
 
chain disease. 
 
 
3.1 Cytogenetic studies 
 
Cytogenetic studies were performed on all of the patients in the prospective 
arm of the study. Success was however limited due to unavailability of 
metaphases in most patients. The main problem appears to have been failure 
to achieve growth, irrespective of whether the specimens were fresh or had 
adequate tumour representation. A successful result was obtained in 1/20  
(5%) of the patients studied.  The abnormality detected was hyperdiploidy (50-
59 chromosomes). 
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3.2   Flourescence In Situ Hybridisation (FISH) 
 
With regard to FISH analysis five of the twenty (5/20) patients (25%) were  
 
found to be positive for deletion 13q14, locus D13S319. This result is lower  
 
than that reported in other studies (Zojer et al, 2000; Chang et al, 1999;  
 
Perez-Simon et al, 1998).  
 
 
 
 
Figure 1.7 Interphase cell showing normal signals for chromosome 13q probe,  
 
                 two red 13q and two green signals for the control probe. 
 
 
 
 
 
Figure 1.8  Interphase cell showing deletion of chromosome 13q14  
 
(D13S319)  with only one red signal. The two green signals represent the  
 
control probe. 
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Figure 1.9 The three green signals, demonstrate Trisomy of chromosome 11,  
                 which was used as a control probe.  
 
 
 
 
 
 
 
 
Figure 1.10 Three green signals demonstrate Trisomy 18, which was used as 
a control probe. 
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Table 1.1 Patients Characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SID = Study ID; WCC = white cell count; HB = Haemoglobin; CRP = C-Reactive Protein; PLTS = Platelets; BM % Pl Cells = 
Percentage bone marrow plasma cells; Paraprotein = Paraprotein level; Urine BJP = Urine Bence Jones Protein; Pos= positive; 
Neg = negative.*Result not available 
SID Age 
Yrs 
Gender WCC
x  
10^9/l 
HB 
g/dl 
Plts x 
10^9/l 
CRP BM % 
Pl. 
Cells 
Para- 
protein. IgG  g/l 
IgA  
g/l 
IgM 
g/l 
Urine 
(BJP) 
1 69 M 6,7 8,9 187 13 85% 70 93,5 0,25 0,81 Neg 
2 52 M 8,8 6,1 106 150 35% 51,24 2,52 50,4 <0,25 Pos 
3 60 M 5,3 6,1 215 * 40% 64,3 3,34 88,3 <0,25 0,61 
4 55 M 9,8 9,4 247 * 22% 46,0 46,0 0,79 0,62 1,69 
5 50 M 4,10 7,5 231 55 84% 21,5 6,53 0,58 <0,25 6,85 
6 54 F 4,89 9,4 277 * 50% 69,2 91,8 0,51 0,38 Pos 
7 35 M 6,6 16,6 278 32 42% 5,44 12,20 0,68 0,47 0,41 
8 67 F 5,65 10,9 231 * 37% 46,6 58,2 0,40 <0,25 0,90 
9 60 M 8,9 12,5 215 * <1% 7,94 13,2 1,04 0,61 3,2 
10 44 M 2,41 8,6 324 * * 38,5 42,6 <0,25 <0,26 * 
11 55 F 5,84 5,2 381 150 89% 71,24 2,78 72,5 <0,25 1,36 
12 59 M 4,8 9,4 186 114 44% 75,2 78,4 <0,25 0,63 Pos 
13 60 M 3,5 9,2 187 * * 63,8 2,67 84,4 <0,25 0,44 
14 50 M 4,96 5,6 93 106 33% 94,2 107 <0,25 0,27 5,63 
15 69 M 7,08 6,3 290 * 14% 69,6 113 <0,25 <0,25 0,09 
16 65 M 2,76 4,3 69 * 70% 85,3 108 0,33 <0,25 * 
17 65 M 5,11 9,8* 174 * 60% 38.2 48 1,00 0,53 * 
18 77 F 9,1 9,4 224 * 45% 43,6 77,9 0,32 0,26 * 
19 54 F 5,8 11,9 350 34 15% 15,1 21,7 1,90 0,59 0,6 
20 49 M 9,2 7,8 419 * * 79,3 * 79,3 * Pos 
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Table 1.2  Patients  Characteristics  
SID Urea 
mmol/l 
Creat 
Umol/l 
Tprot  
g/l 
Alb 
g/l 
B2-M 
mg/l 
Cal 
mmol/l 
Stage Cyto FISH 
1 1,4 156 120 30 7,05 2,51 IIIa Uns Neg 
2 14,7 464 97 18 >4 2,63 IIIb Uns Neg 
3 20,3 294 35 2,14 * 2,28 IIIa Uns Neg 
4 3,7 47 79 23 1,9 2,04 Ia Uns Neg 
5 23,7 415 88 29 4,0 2,22 IIIb Uns Neg 
6 7,8 195 120 32 11,7 3,19 IIIb Uns Neg 
7 2,5 95 76 45 1,7 2,29 Ia Uns Pos/Tri18 
 
8 19,3 263 >120 35 4 2,47 IIa Uns Neg 
9 10,7 437 79 43 * 3,69 IIIb Uns Neg 
10 13 282 96 31 15,3 2,08 IIIB Uns Neg 
11 5,2 145 118 25 * 3,65 IIIa Uns Pos 
12 3,7 104 120 22 4,0 2,81 Ia Uns Neg 
13 6,2 105 120 31 4,0 2,36 IIIa 50/59 
Chr 
Neg 
14 5,1 144 120 18 6,4 2,74 IIIb Uns Neg/Tri11 
 
15 6,2 106 84 31 11 2,48 IIIa Uns Neg 
16 25,5 537 120 17 23,47 309 IIIb Uns Pos/Tri11 
 
17 13.1 455 101 34 14,9 2,39 IIIa Uns Pos 
18 6,2 70 120 35 * 2,96 IIIb Uns Neg/Tri11 
 
19 6,9 72 96 39 1,6 N Ia Uns Pos/Tri11 
20 2,6 81 * * 7,0 2,28 IIIa Uns Neg 
 
Creat = Creatinine; Tprot = Total protein; Alb = Albumin; B2-M = Beta-2 
Microglobulin; Cal = Calcium; Stage = Disease stage, 
 Cyto = Cytogenetic studies, Uns = Unsuccessful; FISH = Fluoresence in situ 
hybridisation 
Pos = positive for deletion 13q14 (D13S319), Neg = negative for the 
deletion,Tri = trisomy 
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Table 1.3 Factors of prognostic significance in patients at CHBH. 
 (Patel et al, 2000)   
 
 
 
LTFU –lost to follow up, Neg – negative, Pos - positive, Tri11- trisomy 11, 
Tri18 - trisomy18, Surv -Survival, Out-Outcome.  
  
 SID Wcc Hb Plts Crp Urea Creat. Ca B-2-
micr 
Para 
Prot 
Stag
e 
FISH Out Surv 
mth 
     1 6,7 8,9 187 8,9 1,4 156 2,51 7,05 70 IIIa Neg Died 0,75 
     2 8,8 6,1 106 6,1 14,7 464 2,63 > 4 51,24 IIIb Neg Died 0,75 
     3 5,3 6,1 215 * 20,3 294 2,28 * 64,0 IIIa Neg Aliv 49 
     4 9,8 9,4 247 * 3,7 47 2,04 1,9 46,0 IIa Neg Died 1 
     5 4,10 7,5 231 * 23,7 415 2,22 4,0 21,5 IIIb Neg Died 0,75 
     6 4,89 9,4 277 * 7,8 195 3,19 11,7 69,2 IIIb Neg  1 
     7 6,6 16,6 278 * 2,5 95 2,29 1,7 5,44 Ia Pos/Tri 
18 
Aliv 60 
     8 5,65 10,9 231 * 19,3 263 2,47 4 58,2 IIa Neg Died 3 
     9 8,9 12,5 215 * 10,7 437 3,69 * 7,94 IIIb Neg Died 0,5 
   10 2,41 8,6 324 * 13 282 2,08 15,3 38,5 IIIb Neg LTFU - 
   11 5,84 5,2 381 * 5,2 145 3,65 * 71,24 IIIa Pos Died 8 
   12 4,8 9,4 186 114 3,7 104 2,81 4,0 75,2 Ia Neg Died 4 
   13 3,5 9,2 187 * 6,2 105 2,36 4,0 63,8 IIIa Neg Aliv 36 
   14 4,96 5,6 93 106 5,1 144 2,74 6,4 94,2 IIIb Neg Died 11 
   15 7,08 6,3 290 * 6,2 106 2,48 11 69,6 IIIa Neg Aliv 41 
   16 2,76 4,3 69 * 25,5 537 3,09 23,4 85,3 IIIb Pos/Tri
11 
LTFU - 
   17 5,11 9,8 174 * 13,1 455 2,39 14,9 38,2 IIIa Pos Died 4 
   18 9,1 9,4 224 * 6,2 70 2,96 * 43,6 IIIb Neg/Tri
11 
Died 3 
   19 5,8 11,9 350 34 6,9 72 N N 15,1 Ia Pos/Tri
11 
LTFU - 
   20 9,2 7,8 419 * 2,6 81 2,28 7,0 79,3 IIIa Neg Died 3m 
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CHAPTER 4 
 
4.0 STATISTICAL_ANALYSIS 
 
The statistical analysis was carried out using non-parametric data analysis methods,  
 
the U-test of Mann-Whitney and the Fisher exact test. Analyse-it for excel and  
 
SigmaStat software were utilised. 
 
The detection rate of chromosomal aberrations improved significantly with FISH  
 
compared to conventional cytogenetics (5% vs 25%).  
 
Although both cytogenetics and FISH analysis showed a low detection rate for  
 
Chromosome 13q14, compared to other studies, there was a poor measure of  
 
agreement between the two methods. 
 
There was no statistically significant difference in mortality between patients with the  
 
chromosomal abnormality (13q14, D13S319)   compared to  those without the  
chromosomal abnormality (Chi-Square=3.4182 P=0.181), although more patients  
without the chromosomal abnormality died (66,67%) and two patients with the  
chromosomal abnormality died.  The median survival was 3 months for patients  
without the 13q14 deletion and 8 months for patients with the 13q14 deletion. 
 
Figure 1.11 
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 However, in view of the small patient numbers studied, definite conclusions cannot  
 
be made. 
 
 
Two of the patients with the chromosomal aberration were lost to follow up, so their  
 
survival could not be calculated. 
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 Of the patients where survival could be calculated, two with the chromosomal  
 
abnormality  had a survival period  similar to that of patients without the chromosomal  
 
aberration and one patient with the chromosomal aberration and trisomy 18 had  
 
prolonged survival (60 months). 
 
 Of note is that he presented at a young age (35 years), with early disease (stage-Ia).  
 
He also had other favourable prognostic features (i.e  Hb = 16.6g/dl; 
 
Beta-2 microglobulin = 1.4; Calcium = 2.29 and normal renal function).  
 
No correlation was found between the stage of the disease and the presence of the  
 
chromosomal abnormality (13q14, D13S319) . The majority of the patients without  
 
the chromosomal abnormality presented with advanced stage disease. Late 
 
presentations with advanced stage disease is not unusual in our patient population. 
 
This could  explain the high mortality rate in these patients. 
 
A positive correlation was found between disease stage and mortality, in that most  
 
patients with stage III died compared to patients in stage I and II. 
 
Comparison of laboratory results to disease stage showed statistically significant  
 
differences for Creatinine, Beta -2 microglobulin and Haemoglobin level. Patients  
 
with disease stage III showed a higher creatinine and Beta-2 microglobulin level and  
 
lower haemoglobin levels compared to patients with early stage disease (I and II).  
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CHAPTER 5 
 
5.0 DISCUSSION  
 
The detection of chromosomal abnormalities in MM has always been a  
 
problem, because of the low proliferation rate of the plasma cells. 
 
This has however improved significantly with the introduction of the FISH  
 
technique, since this does not require metaphases for analysis. We also  
 
found that the detection rate of chromosomal abnormalities improved  
 
significantly  in our patients with FISH analysis. This was attributed to the   
 
difficulty to achieve growth and thus failure to obtain analysable metaphases  
 
from the cell cultures. 
 
Chromosome 13q14: Deletion 13q14, D13S319 was detected in five of the  
 
twenty (5/20) patients compared to only one patient where hyperdiploidy 
 
 (50-59 chromosomes) was detected with cytogenetics studies. This  
 
patient did not have a positive FISH result for  13q14,D13S319. 
 
The frequency of 25% of 13q14 deletion in our patients is much lower  
 
than that reported by other groups in the literature (i.e 30 to 70%), despite the  
 
fact that the majority of the patients presented with advanced stage disease. 
 
 The reasons for the low detection rate of this abnormality in our patients are  
 
not entirely clear, but the possibilities include: 
 
- A low prevalence of this abnormality in our patient population. 
 
- The presence of other chromosomal abnormalities e.g   
 
     chromosomes 14 and chromosome 17 abnormalities which are also  
 
    known to occur in MM  and confer a poor prognosis but were not        
 
    assessed in this study. 
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- The  different types of probes used by the different study groups. 
 
We used a probe specific for D13S319, whereas most of the other  
 
studies used  probes extending from the RB-1 gene covering a wider  
 
region of the chromosome. Chang et al (1999), used a similar probe but  
 
reported a slightly higher frequency (30%).  
 
-  The variation in the frequency and location of deletions of 13q14 is well  
 
documented (J. Shaughnessy  et al, 2000). The absence of deletion  
 
D13S319 does not exclude other deletions of 13q14.  Ideally the whole  
 
extent of 13q should be studied in detail to determine the minimum  
 
deleted region in MM. 
 
- Technical reasons have to be considered as well. These include: 
 
       i) Very poor yield on conventional cytogenetics 
 
       ii) Inadequate tumour representation in the bone marrow samples. 
 
iii) Failure of hybridisation because of the aged/ dehydrated  
 
      specimens,  and 
 
       iv) Non-specific representation of the plasma cells due to lack of      
        
       purification/sorting of the tumour cells. 
 
  
 
Chromosome 11: Abnormalities of chromosome 11 are said to be common in 
 
 MM.  Four (20%) of our patients showed trisomy of chromosome11. Two of  
 
those also had deletion 13q14 (D13S319). The three patients with trisomy 11   
 
who presented with disease  stage III died , and one was lost to follow-up.  
 
The specific role of chromosome 11 abnormalities in the  
 
pathogenesis of MM is not known. The t (11; 14) has however been  
 
associated  with a poor prognosis in MM. 
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Chromosome 18:  Abnormalities of chromosome 18 have also been  
 
described in MM, including trisomy 18.  Trisomy 18 has been found to occur in  
 
up to 10% of patients with MM, but apparently not been found to be of 
 
 prognostic significance. In this study one patient with deletion 13q14  
 
(D13S319) was found to be positive for trisomy of chromosome 18. 
 
The significance of this finding is not certain.   
 
Generally trisomies are common in MM corresponding to the  
 
hyperdiploidy status of these cells,  and chromosomal gains are apparently   
 
generally associated  with poor prognosis ( Fonseca et al, 1999) 
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CHAPTER 6 
 
6.0 CONCLUSION 
 
The occurance of chromosomal abnormalities is well documented in  
 
MM. These may involve a number of chromosomes, and may manifest as   
 
deletions,  trisomies,  monosomies or translocations.  These include more  
 
importantly  abnormalities of chromosomes  11,14,13,17,16.  
 
Some chromosomal abnormalities have been found to have prognostic  
 
significance. 
 
Deletions of chromosome 13 have specifically been associated with a poor  
 
prognosis, despite conventional chemotherapy. It is however not known  
 
whether the poor  prognosis is as a result of the deletion in isolation, or  in  
 
association with abnormalities of chromosome 14q32  with the various  
 
partners and the hypodiploidy  which frequently co-exists.   
 
In this study we also set out to determine whether there was any correlation  
 
between the  presence of deletion 13q14, D13S319 and other known 
 
prognostic factors in our patients. 
 
The prevalence of 13q14 deletion in our patients was lower than that reported  
 
in the literature (25% vs 30-80%). There was no correlation found between  
 
the presence of deletion 13q14 and mortality, stage of disease and known  
 
laboratory  parameters  associated with poor prognosis in MM. 
 
The prognostic significance of deletion 13q14(D13S319) in MM could not be  
 
established from this study. 
 
The limitations of this study includes the small sample size, the unavailability  
 
of a built-in control  for the specific probe,  which necessitated the use of  
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additional centromeric probes as external controls, which showed 
 
 abnormalities.  The FISH technique also required optimisation for  
 
old specimens. This was ultimately achieved,  though  in a limited number of  
 
patients. 
  
The use of fresh specimens and sorting of the tumour cells is recommended  
 
to improve yield and quality of results. A probe with a built-in control would be      
 
preferable.  
 
A further prospective study with a larger patient sample using probes covering  
 
the whole extent of chromosome 13q may yield more conclusive results. 
 
The use of alternative techniques such as analysis of gene expression  
 
profiles/signatures to further investigate genes that might be responsible for  
 
the poor prognosis in MM should also be considered. 
 
 Numerous groups have shown that classification on the basis of gene  
 
expression signatures is plausible , with  the possibility of  making definitive   
 
diagnosis upfront, monitoring  disease evolution  and predicting prognosis. 
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APPENDIX 1 
Multiple Myeloma – Disease Staging System 
 
The staging system gives an indication of the tumor load and is based on a  
 
number of prognostic factors (Durie and Salmon, 1975) 
 
Stage Criteria Measured myeloma cell 
Mass (cell x1012 /m2 
I 1. Haemoglobin >10g/dl 
2.Normal Serum Calcium (<12mg/dl) 
3.Normal bone structure (scale 0) or 
solitary bone plasmacytoma 
4.Low M-component production rate 
a.IgG value <50g/l 
b. IgA value <30g/l 
c. Urine light chain M-component on 
electrophoresis <4g/24h 
< 0,6 (low) 
II Fitting neither stage I or II 0,6-1,2 (intermediate) 
III 1. Haemoglobin <8,5g/dl 
2. Serum Calcium >12mg/dl 
3. Advanced lytic bone lesions 
(scale 3) 
High M-component production rates 
IgG >70g/l 
IgA > 50g/l 
Urine light chain M-component on 
electrophoresis >12g/24hrs 
A - relatively normal renal function (serum 
creatinine <2mg/dl) 
B -  abnormal renal function (serum 
creatinine >2mg/dl) 
> 1,2 (high) 
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APPENDIX 2 
Criteria for diagnosis of Myeloma 
Any 2 major criteria listed below 
Major criterion 1 plus minor criterion B, C or D 
Major criterion 3 plus minor criterion A or C 
Minor criteria A, B and C or A, B and D 
MAJOR CRITERIA 
1. Plasmacytoma on biopsy 
2. > 30% plasma cells in marrow 
3. Monoclonal immunoglobulin electrophoretic spike with IgG >3,5 g/dl 
or IgA > 2 g/dl or kappa or lambda light chain excretion in the  
urine > 1g /day 
MINOR CRITERIA 
A. Bone marrow plasmacytosis, with 10-30% plasma cells 
B. Monoclonal immunoglobulin present, but at quantitatively lower levels 
than for a major criteria 
C. Lytic bone lesions 
D.  Depressed normal immunoglobulins IgM<50 mg/dl, IgA < 100 mg/dl, 
IgG < 600 mg/dl. 
( Durie, 1986, Committee of Chronic Leukemia-Myeloma Task Force, 
National Cancer Institute, 1993) 
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APPENDIX 3 
Criteria for Diagnosis of Myeloma 
All three required 
M-protein in serum or urine or both 
Bone marrow (clonal) plasma cells or plasmacytoma 
Related organ or tissue impairment (one or more of the following) 
 C = hypercalcemia (serum calcium 0,25 mmol/l above the upper normal        
limit or ≥ 2,75 mmol/l) 
 R = renal insufficiency (creatinine ≥ 173 umol/l or 2 mg/dl) 
 A = anaemia (haemoglobin 2 g/dl below the lower normal limit or 
haemoglobin ≤ 10g/dl) 
 B = bone lesions (lytic lesions or osteoporosis with compression fracture) 
 Other = symptomatic hyperviscosity, amyloidosis, recurrent bacterial 
infections (> 2 episodes in 12 months) 
- No minimal level of serum M-protein or urine M-protein was included in 
the criteria. 
- No minimal levels of clonal bone marrow plasma cells was designated. 
- The most critical criterion is the evidence of end organ or tissue 
impairment. 
(International Myeloma Work Group Criteria for the classification of 
monoclonal gammopathies, multiple myeloma and related disorders: a 
report of the International Myeloma Working Group. Br. J Haem. 
2003,121:749-757).  
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Appendix 4 
 
Risk Classification in Multiple Myeloma 
Standard Risk (5 year survival) High Risk (2-3 years survival) 
Hyperdiploid Hypodiploid 
Beta-2 microglobulin <5,5 mg/l t(4;14), t(14;16) 
Normal LDH Deletion 17p 
Deletion 17p, t(4;14), t(14;16) 
t(11;14), t(6;14) 
Deletion 13q 
 Plasma cell labelling index >3% 
 
